
Denosis60 mg/ml
Incepta Pharmaceuticals Ltd.
Denosumab is a human monoclonal antibody (RANK ligand inhibitor) marketed under different brand names and dosing schedules depending on indication.
Denosumab is a human monoclonal antibody (RANK ligand inhibitor) marketed under different brand names and dosing schedules depending on indication. Approved uses include:
The osteoporosis-dose formulation of Denosumab and the higher oncology-dose formulation of Denosumab are not interchangeable; the correct brand/strength depends on the indication.
| Indication | Dose | Frequency |
|---|---|---|
| Postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, hormone-ablation-related bone loss | Denosumab 60 mg subcutaneously | Once every 6 months |
| Indication | Dose | Frequency |
|---|---|---|
| Prevention of SREs in bone metastases from solid tumors or multiple myeloma | Denosumab 120 mg subcutaneously | Once every 4 weeks |
Denosumab 120 mg subcutaneously every 4 weeks, with additional 120 mg doses on days 8 and 15 of the first month of therapy (loading doses).
Denosumab 120 mg subcutaneously every 4 weeks, with additional 120 mg doses on days 8 and 15 of the first month of therapy.
All patients receiving Denosumab should have adequate calcium and vitamin D supplementation, particularly during the first weeks of treatment. See Administration for injection technique and Precautions for pre-treatment evaluation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.